

LA JOLLA PHARMACEUTICAL CO  
 Form 4  
 June 15, 2007

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Gonzalez Alejandro

2. Issuer Name and Ticker or Trading Symbol  
 LA JOLLA PHARMACEUTICAL CO [LIPC]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)

RUBEN DARIO #223  
 5-A, CHAPULTEPEC MORALES,  
 MEXICO D.F. 11570

3. Date of Earliest Transaction (Month/Day/Year)  
 06/14/2007

\_\_\_\_ Director  
 \_\_\_\_ Officer (give title below)  
 10% Owner  
 \_\_\_\_ Other (specify below)

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |
| Common Stock                    | 06/14/2007                           |  | P                              |   | 67,000  | A  | \$ 4.59   |
| Common Stock                    | 06/14/2007                           |  | P                              |   | 11,647  | A  | \$ 4.6  |
| Common Stock                    | 06/14/2007                           |  | P                              |   | 37,500  | A  | \$ 4.61   |
| Common Stock                    | 06/14/2007                           |  | P                              |   | 4,200   | A  | \$ 4.62   |
|                                 | 06/14/2007                           |  | P                              |   | 63,291  | A  | 5,613,466   |

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

|              |            |  |   |         |      |      |           |   |
|--------------|------------|--|---|---------|------|------|-----------|---|
| Common Stock |            |  |   |         | \$   |      |           |   |
|              |            |  |   |         | 4.63 |      |           |   |
| Common Stock | 06/14/2007 |  | P | 26,646  | A    | \$   | 5,640,112 | D |
|              |            |  |   |         |      | 4.64 |           |   |
| Common Stock | 06/14/2007 |  | P | 189,716 | A    | \$   | 5,829,828 | D |
|              |            |  |   |         |      | 4.65 |           |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Nu... Deriv... Secur... Bene... Own... Follo... Repo... Trans... (Instr... |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|

  

|  |  |  |  |      |           |                  |                 |       |                            |
|--|--|--|--|------|-----------|------------------|-----------------|-------|----------------------------|
|  |  |  |  | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
|--|--|--|--|------|-----------|------------------|-----------------|-------|----------------------------|

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director    10% Owner    Officer    Other

Gonzalez Alejandro  
RUBEN DARIO #223 5-A  
CHAPULTEPEC MORALES, MEXICO D.F. 11570

X

## Signatures

/s/ Alejandro Gonzalez                      06/15/2007

\*\*Signature of Reporting Person                      Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.